Why GenMark Diagnostics Stock Is Soaring Today
Shares of GenMark Diagnostics (NASDAQ: GNMK) were soaring 21.6% as of 11:44 a.m. EDT on Wednesday. The big jump came after GenMark provided preliminary second-quarter results Tuesday evening.
It's easy to see why investors reacted positively to GenMark's Q2 sneak peek. The molecular diagnostics testing company expects revenue of around $40.1 million, up 118% year over year. Most of this total will likely stem from GenMark's ePlex diagnostic platform. The company projects Q2 ePlex sales of around $35.2 million, nearly triple the amount made in the prior-year period.
Image source: Getty Images.
Source Fool.com
